|Articles|February 4, 2009
Avastin for myopic CNV
Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study
Advertisement
Please click
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
2
FLORetina 2025: New horizons in research and risk management for ROP
3
FLORetina 2025: Enrico Borrelli on reframing retinal disease through the lens of choroidal health
4
FLORetina 2025: Antithrombotic use examined in wet AMD submacular hemorrhage
5









































